



632

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61K 49/00		A2	(11) International Publication Number: <b>WO 99/36104</b>  (43) International Publication Date: 22 July 1999 (22.07.99)
<p>(21) International Application Number: PCT/US99/00747</p> <p>(22) International Filing Date: 14 January 1999 (14.01.99)</p> <p>(30) Priority Data: 60/071,332 14 January 1998 (14.01.98) US</p> <p>(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US).</p> <p>(72) Inventors: HUI, Poh, K.; 45 Wareland Road, Wellesley, MA 02181 (US). BISHOP, John, E.; 878 Townsend Road, Groton, MA 01450 (US). MADRIGAL, Eleodoro, S., Jr.; Apartment 12, 14B Strawberry Hill Road, Acton, MA 01720 (US).</p> <p>(74) Agent: O'BRIEN, Maureen, P.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).</p>		<p>(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND</p> <p>(57) Abstract</p> <p>The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

TitlePREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION  
CONTAINING THE LIPID BLEND

5

Field of the Invention

The present invention relates generally to processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.

Background of the Invention

Manufacturing of a phospholipid contrast agent can be divided into the following steps: (1) preparation of lipid blend; (2) compounding the bulk solution, which involves the hydration and dispersion of the lipid blend in an essentially aqueous medium to produce a lipid suspension; (3) filtration of the bulk solution through a sterilizing filter(s) to render the suspension free of microbial contaminants; (4) dispensing the sterile suspension into individual vials in a controlled aseptic area; (5) loading the dispensed vials into a lyophilizer chamber to replace the vial headspace gas with perfluoropropane gas (PFP); (6) transferring the sealed vials after gas exchange to an autoclave for terminal sterilization. There are three major obstacles in this process: (1) uniformity of the lipid blend; (2) hydration of the lipid blend; (3) uniformity and particle size of the suspension; and, (4) sterile filtration of the suspension through a sterilizing filter(s).

Phospholipid blends are typically produced by dissolving or suspending the required lipids in an appropriate aqueous or non-aqueous solvent system, and then reducing the volume either by lyophilization or distillation. Ideally, this process produces blended solids with high content uniformity and purity. However, while working well on a small, laboratory scale, this simple approach is frequently problematic upon scale-up to

production-size quantities. Difficulties include: (1) maintaining content uniformity during the solvent removal step (due to differential solubilities); (2) maintaining purity (frequently a problem when water is used due to 5 hydrolytic side-reactions); (3) enhancing purity; (4) minimizing solvent volume; and (5) recovery of the final solids (e.g., it is not practical to scrape solids out of a large reactor).

After manufacture of a lipid blend, final compounding 10 typically involves introduction of the blend into an aqueous medium. Since phospholipids are hydrophobic and are not readily soluble in water, adding phospholipids or a lipid blend directly into an aqueous solution causes the lipid powder to aggregate forming clumps that are very difficult 15 to disperse. Thus, the hydration process cannot be controlled within a reasonable process time. Direct hydration of phospholipids or a lipid blend in an aqueous medium produces a cloudy suspension with particles ranging from 0.6  $\mu\text{m}$  to 100  $\mu\text{m}$ . Due to relatively large particle 20 size distribution, the suspension cannot be filtered at ambient temperature when the suspension solution temperature is below the gel-to-liquid crystal phase transition 25 temperatures of lipids. The lipids would accumulate in the filters causing a restriction in the flow rate, and in most cases, the filters would be completely blocked shortly after. Further reduction in the suspension particle size cannot be achieved through a conventional batching process, even after extended mixing (e.g., 6 hours) at elevated 30 temperatures (e.g., 40°C to 80°C) with a commonly used marine propeller.

Although filtration at elevated temperatures, i.e., at 35 above the phase transition temperatures of lipids, is possible, a significant amount of larger lipid particles would still be excluded when a normal filtering pressure is used. In turn, concentrations of the sterile filtrate would have variable lipid content from batch to batch depending on how the lipids are initially hydrated which is in turn

determined by the physical characteristics, e.g., morphology, of the starting materials.

The process of directly hydrating the lipids or lipid blend to produce a uniform suspension and filtration of the 5 suspension through a sterilization filter(s) can be difficult and costly to be scaled-up to any reasonable commercial scale, e.g., >20L.

Thus, the presently claimed processes for manufacture of a lipid blend and the subsequent phospholipid suspension 10 are aimed at solving the above issues by providing a practical process that can be easily scaled and adopted to various manufacturing facilities without extensive modification or customization of existing equipment.

15 Summary of the Invention

Accordingly, one object of the present invention is to provide a novel process for preparing a lipid blend.

Another object of the present invention is to provide a novel process for preparing a phospholipid suspension from 20 the lipid blend.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that dissolving a lipid blend in a suitable non-aqueous solvent prior to 25 introduction of an aqueous solution allows for production of a phospholipid suspension.

Detailed Description of the Invention

[1] Thus, in a first embodiment, the present invention 30 provides a novel process for preparing a phospholipid suspension, comprising:

(1) contacting a lipid blend with a non-aqueous solvent, whereby the lipid blend substantially dissolves in the non-aqueous solvent; and,

35 (2) contacting the solution from step (1) with an aqueous solution to form a lipid suspension.

[2] In a preferred embodiment, the non-aqueous solvent is selected from propylene glycol, ethylene glycol, and polyethylene glycol 300.

5 [3] In a more preferred embodiment, the non-aqueous solvent is propylene glycol.

[4] In another preferred embodiment, the lipid blend, comprises:

10 (a) 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine;  
(b) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt; and,  
(c) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt.

15 [5] In another preferred embodiment, in step (1), the non-aqueous solvent is heated to a temperature of about 30 to 70°C prior to contacting with the lipid blend.

20 [6] In another more preferred embodiment, the non-aqueous solvent is heated to a temperature of about 50 to 55°C prior to contacting with the lipid blend.

25 [7] In another preferred embodiment, the ratio of lipid blend to non-aqueous solvent is from about 5 mg of lipid blend per mL of non-aqueous solvent to about 15 mg/mL.

30 [8] In another more preferred embodiment, the ratio of lipid blend to non-aqueous solvent is about 10 mg/mL.

35 [9] In another preferred embodiment, in step (2), the aqueous solution is selected from water, saline, a saline/glycerin mixture, and a saline/glycerin/non-aqueous solvent mixture.

[10] In another more preferred embodiment, the aqueous solution is a saline and glycerin mixture.

[11] In another more preferred embodiment, the aqueous solution is a saline, glycerin, and propylene glycol mixture.

5

[12] In another more preferred embodiment, 6.8 mg/mL of sodium chloride are present, 0.1 mL/mL of glycerin are present, 0.1 mL/mL of propylene glycol are present, and about 0.75 to 1.0 mg/mL of the lipid blend are present.

10

[13] In an even more preferred embodiment, 0.75 mg/mL of lipid blend are present.

15

[14] In another more preferred embodiment, 1.0 mg/mL of lipid blend are present.

[15] In another preferred embodiment, in step (2), the aqueous solution is heated to a temperature of about 45 to 60°C prior to contacting with the solution from step (1).

20

[16] In another more preferred embodiment, the aqueous solution is heated to a temperature of about 50 to 55°C prior to contacting with the solution from step (1).

25

[17] In another preferred embodiment, the process further comprises:

(3) heating the lipid suspension from step (2) to a temperature about equal to or above the highest gel to liquid crystalline phase transition temperature of the 30 lipids present in the suspension.

35

[18] In another more preferred embodiment, in step (3), the lipid suspension is heated to a temperature of at least about 67°C.

[19] In another more preferred embodiment, the process further comprises:

(4) filtering the lipid suspension through a sterilizing filter.

[20] In another even more preferred embodiment, in step (4), 5 the filtration is performed using two sterilizing filter cartridges.

[21] In a further preferred embodiment, in step (4), the sterilizing filter cartridges are at a temperature of from 10 about 70 to 80°C.

[22] In another further preferred embodiment, in step (4), 0.2µm hydrophilic filters are used.

15 [23] In another even more preferred embodiment, the process further comprises:

(5) dispensing the filtered solution from step (4) into a vial.

20 [24] In another further preferred embodiment, the process further comprises:

(6) exchanging the headspace gas of the vial from step (5) with a perfluorocarbon gas.

25 [25] In another even further preferred embodiment, the perfluorocarbon gas is perfluoropropane.

[26] In another even further preferred embodiment, exchange of headspace gas is performed using a lyophilizing chamber.

30 [27] In another even further preferred embodiment, the process further comprises:

(7) sterilizing the vial from step (6).

35 [28] In a still further preferred embodiment, in step (7), the vial is sterilized at about 126-130°C for 1 to 10 minutes.

[29] In a second embodiment, the present invention provides a novel process for preparing a lipid blend, comprising:

- 5 (a) contacting at least two lipids with a first non-aqueous solvent;
- 10 (b) concentrating the solution to a thick gel;
- (c) contacting the thick gel with a second non-aqueous solvent; and,
- (d) collecting the resulting solids.

15 [30] In a preferred embodiment, in step (a), the lipids are:

- (i) 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine;
- (ii) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt; and,
- (iii) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt.

20 [31] In another preferred embodiment, in step (a), the first non-aqueous solvent is a mixture of methanol and toluene.

[32] In another preferred embodiment, in step (c), the second non-aqueous solvent is a methyl t-butyl ether.

25 [33] In another preferred embodiment, in step (a), the solution is warmed to a temperature sufficient to complete dissolution of the lipids into the solvent.

30 [34] In another more preferred embodiment, in step (a), the solution is warmed to about 25 to 75°C.

[35] In another preferred embodiment, in step (d), the solids collected are washed with methyl t-butyl ether and dried in vacuo.

35

[36] In a third embodiment, the present invention provides a novel phospholipid suspension, comprising:

- (a) a lipid blend in an amount of about 0.75 - 1.0 mg/mL of suspension;
- (b) sodium chloride in an amount of about 6.8 mg/mL of suspension;
- 5 (c) glycerin in an amount of about 0.1 mL/mL of suspension;
- (d) propylene glycol in an amount of about 0.1 mL/mL of suspension; and
- (e) water;

10 wherein the suspension is prepared by the process, comprising:

- (1) contacting a lipid blend with a non-aqueous solvent, whereby the lipid blend substantially dissolves in the non-aqueous solvent;
- 15 (2) contacting the solution from step (1) with an aqueous solution to form a lipid suspension;
- (3) heating the lipid suspension from step (2) to a temperature about equal to or above the highest gel to liquid crystalline phase transition temperature of the
- 20 lipids present in the suspension; and,
- (4) filtering the lipid suspension through a sterilizing filter.

[37] In another preferred embodiment, the lipid blend, 25 comprises:

- (a) 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine;
- (b) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt; and,
- (c) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt.

[38] In another more preferred embodiment, the non-aqueous solvent is heated to a temperature of about 50 to 55°C prior 35 to contacting with the lipid blend.

[39] In another more preferred embodiment, the ratio of lipid blend to non-aqueous solvent is about 10 mg/mL.

[40] In another more preferred embodiment, the aqueous solution is a saline, glycerin, and propylene glycol mixture.

5

[41] In an ever more preferred embodiment, 0.75 mg/mL of lipid blend are present.

10 [42] In another more preferred embodiment, the aqueous solution is heated to a temperature of about 50 to 55°C prior to contacting with the solution from step (1).

15 [43] In another more preferred embodiment, in step (3), the lipid suspension is heated to a temperature of at least about 67°C.

20 [44] In another further preferred embodiment, in step (4), two 0.2µm hydrophilic filters are used.

#### Formulation

25 The present invention is contemplated to be practiced on at least a multigram scale, kilogram scale, multikilogram scale, or industrial scale. Multigram scale, as used herein, is preferably the scale wherein at least one starting material is present in 10 grams or more, more preferably at least 50 grams or more, even more preferably at least 100 grams or more. Multikilogram scale, as used herein, is intended to mean the scale wherein more than one kilogram of at least one starting material is used.

30 Industrial scale as used herein is intended to mean a scale which is other than a laboratory scale and which is sufficient to supply product sufficient for either clinical tests or distribution to consumers.

35 Lipid blend or phospholipid blend, as used herein, is intended to represent two or more lipids which have been blended. The lipid blend is generally in a powder form. Preferably, at least one of the lipids is a phospholipid. Preferably, the lipid blend contains 1,2-dipalmitoyl-sn-

glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt (DPPA), and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000-DPPE). The amount of each lipid present in the blend will depend on the desired end product. Preferred ratios of each lipid are described in the Examples section. A wide variety of other lipids, like those described in Unger et al, U.S. Patent No. 5,469,854, the contents of which are hereby incorporated by reference, may be used in the present process.

10 Phospholipid, as used herein, is a fatty substance containing an oily (hydrophobic) hydrocarbon chain(s) with a polar (hydrophilic) phosphoric head group. Phospholipids 15 are amphiphilic. They spontaneously form boundaries and closed vesicles in aqueous media. Phospholipids constitute about 50% of the mass of animal cell plasma membrane.

#### Preparation of the lipid blend

20 The lipid blend may be prepared via an aqueous suspension-lyophilization process or an organic solvent dissolution-precipitation process using organic solvents. In the aqueous suspension-lyophilization process, the desired lipids are suspended in water at an elevated 25 temperature and then concentrated by lyophilization. Preferably a dissolution procedure is used.

#### Step (a):

30 The organic solvent dissolution-precipitation procedure involves contacting the desired lipids (e.g., DPPA, DPPC, and MPEG5000 DPPE) with a first non-aqueous solvent system. This system is typically a combination of solvents, for example CHCl<sub>3</sub>/MeOH, CH<sub>2</sub>Cl<sub>2</sub>/MeOH, and toluene/MeOH. Preferably, the first non-aqueous solvent is a mixture of 35 toluene and methanol. It may be desirable to warm the lipid solution to a temperature sufficient to achieve complete dissolution. Such a temperature is preferably about 25 to 75°C, more preferably about 35 to 65°C.

After dissolution, it may be desired to remove undissolved foreign matter by hot-filtration or cooling to room temperature and then filtering. Known methods of filtration may be used (e.g., gravity filtration, vacuum filtration, or pressure filtration).

5 Step (b):

The solution is then concentrated to a thick gel/semisolid. Concentration is preferably done by vacuum distillation. Other methods of concentrating the solution, such as rotary evaporation, may also be used. The temperature of this step is preferably about 20 to 60°C, more preferably 30 to 50°C.

15 Step (c):

The thick gel/semisolid is then dispersed in a second non-aqueous solvent. The mixture is slurried, preferably near ambient temperature (e.g., 15-30°C). Useful second non-aqueous solvents are those that cause the lipids to precipitate from the filtered solution. The second non-aqueous solvent is preferably methyl *t*-butyl ether (MTBE). Other ethers and alcohols may be used.

25 Step (d):

The solids produced upon addition of the second non-aqueous solvent are then collected. Preferably the collected solids are washed with another portion of the second non-aqueous solvent (e.g., MTBE). Collection may be performed via vacuum filtration or centrifugation, preferably at ambient temperature. After collection, it is preferred that the solids are dried in *vacuo* at a temperature of about 20-60°C.

30 For the following reasons, the organic solvent dissolution-precipitation process is preferred over the aqueous suspension/lyophilization process:

(1) Because the lipids are quite soluble in toluene/methanol, solvent volumes are significantly reduced (relative to the aqueous procedure).

(2) Because of this increased solubility, the process 5 temperature is also lower relative to the aqueous procedure, thereby avoiding the hydrolytic instability of fatty acid esters.

(3) When cooled back to room temperature, the toluene/methanol solution of lipids remains homogeneous, 10 allowing a room temperature filtration to remove solid foreign matter.

(4) The MTBE precipitation allows quick and easy isolation of Lipid Blend solids. With the aqueous process, a time-consuming lyophilization process is used to isolate 15 material.

(5) The MTBE precipitation also allows for the removal of any MTBE-soluble impurities, which go into the filtrate waste-stream. This potential for impurity removal is not realized when a solution is directly concentrated or 20 lyophilized to a solid.

(6) The present process affords uniform solids.

Preparation of the lipid suspension

Step (1):

25 In step one, a lipid blend is contacted with a non-aqueous solvent, whereby the lipid blend substantially dissolves in the non-aqueous solvent. Alternatively, the individual lipids may be contacted with the non-aqueous solvent sequentially in the order: DPPC, DPPA, and 30 MPEG5000-DPPE; DPPC, MPEG5000-DPPE, and DPPA; MPEG5000-DPPE, DPPA, and DPPC; or MPEG5000-DPPE, DPPC, and DPPA. The DPPA, being the least soluble and least abundant of the lipids is not added first. Adding one of the other lipids prior to or 35 concurrently with adding the DPPA facilitates dissolution of the DPPA. In another alternative, the individual lipids can be combined in their solid forms and the combination of the solids contacted with the non-aqueous solvent.

Substantial dissolution is generally indicated when the mixture of lipid blend and non-aqueous solvent becomes clear. As noted previously, phospholipids are generally not water soluble. Thus, direct introduction of a blend of 5 phospholipid blend into an aqueous environment causes the lipid blend to aggregate forming clumps that are very difficult to disperse. The present invention overcomes this limitation by dissolving the lipid blend in a non-aqueous solvent prior to introduction of the aqueous solution. This 10 allows one to evenly disperse the lipid blend into a liquid. The liquid dispersion can then be introduced into a desired aqueous environment.

Non-aqueous is intended to mean a solvent or mixture of solvents wherein the amount of water present is sufficiently 15 low as to not impede dissolution of the lipid blend. The amount of non-aqueous solvent required will depend on the solubility of the lipid blend and also the final desired concentration of each component. As one of ordinary skill would appreciate, the level of water present in the non- 20 aqueous solvent, which may be tolerated will vary based on the water solubilities of the individual lipids in the lipid blend. The more water soluble the individual phospholipids, the more water which may be present in step (1). Preferably, propylene glycol is used as the non-aqueous 25 solvent. However, other members of the polyol family, such as ethylene glycol, and polyethylene glycol 300 may be used.

Mechanically mixing the lipid blend and non-aqueous solvent may be necessary to achieve complete dissolution. One of ordinary skill in the art will recognize that a 30 variety of ways of mixing are available. It is preferred that a high shear homogenizer is used.

One of ordinary skill in the art would recognize that raising the temperature of the solvent should aid in dissolution of the lipid blend. The temperature at which 35 step (1) may be performed can range from ambient to the boiling point of the chosen solvent. Preferably the temperature is from about 30 to about 70°C, more preferably about 45 to about 60°C, and even more preferably about 50,

51, 52, 53, 54, or 55°C. When ethylene glycol or polyethylene glycol 300 is used, it is preferred that the temperature be from about 50 to about 60°C and more preferably about 55°C. Maintaining the solution at an 5 elevated temperature should reduce solution viscosity and ease formulation preparation.

A preferred procedure for dissolving the lipid blend is as follows: (a) Add propylene glycol to an appropriate weighing container. (b) Warm the propylene glycol to about 10 40-80°C in a heating bath. (c) Weigh the lipid blend into a separate container. (d) When the propylene glycol has reached the desired temperature range, transfer the solution into the container containing the lipid blend. (e) Place the container back into the heating bath until the solution 15 is clear. (f) Mechanically mix the Lipid Blend/Propylene Glycol solution to further assure complete dissolution and uniform dispersion of the lipid blend.

The ratio of lipid blend to non-aqueous solvent will, of course, be limited by the solubility of the lipid blend. 20 This ratio will also be influenced by the desired amount of lipid blend in the final formulation. Preferably, the ratio is from about 1 mg of lipid blend per mL of solvent (mg/mL) to about 100 mg/mL. More preferably, the lipid blend is present in about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 25 mg/mL. Even more preferably, the lipid blend is present in about 10 mg/mL.

Step (2):

The second step involves contacting the solution from 30 step (1) with an aqueous solution to form a lipid suspension. The aqueous solution can be water, saline, a saline/glycerin mixture or a saline/glycerin/non-aqueous solvent mixture. Non-aqueous solvent is as defined previously, preferably propylene glycol. Suspension, as 35 used herein, is intended to indicate a dispersion in which insoluble particles are dispersed in a liquid medium.

Once complete dissolution of the lipid blend has been achieved (step (1)), the resulting solution can then be

introduced to an aqueous solution. The aqueous solution may contain one or more components selected from sodium chloride, glycerin, and a non-aqueous solvent. Preferably the aqueous solution contains glycerin and sodium chloride.

5 Preferably, a sufficient amount of propylene glycol is present in the aqueous solution, prior to addition of the solution from step 1, in order to achieve the final desired concentration of propylene glycol.

The order of addition of desired components is not 10 expected to seriously impact the resulting lipid suspension. However, it is preferred that the lipid-blend solution is added to water, which may already contain the above-noted additional components. Additional desired components can then be added. It is more preferred that the lipid-blend 15 solution is added a solution of water and sodium chloride (i.e., saline). It is further preferred that the lipid-blend solution is added a solution of water, sodium chloride, and glycerin. It is still further preferred that the lipid-blend solution is added a solution of water, 20 sodium chloride, glycerin, and propylene glycol.

It is preferred that 6.8 mg of NaCl are present per mL of formulation. Preferably, 0.1 mL of Glycerin per mL of formulation is present. A final concentration of 0.1 mL of Propylene Glycol per mL of formulation is preferred. The 25 final pH of the formulation is preferably about 5.5-7.0. The lipid blend is preferably present in an amount of 0.75-1.0 mg/mL of formulation.

The temperature of the aqueous solution can range from 30 ambient to 70°C. Preferably, the temperature is about 45 to 60°C, with 50, 51, 52, 53, 54, or 55 being even more preferred. In order to obtain complete dissolution, the mixture will need to be agitated, preferably stirred. Also, the pH of the solution may need to be adjusted, depending on the desired final formulation. Either acid (e.g., HCl) or 35 base (e.g., NaOH) can be added to make such an adjustment.

The lipid suspension will contain liquid particles of varying sizes. One of the benefits of the present invention is the ability to consistently obtain small particles of a

nearly uniform size. Thus, it is preferred that the majority of particles obtained are less than 100 nm in diameter, more preferable less than 50 nm.

A preferred procedure for dissolving the lipid blend is as follows: (a) Add Water for Injection (WFI) into a compounding vessel. (b) Start mixing and ensure temperature is from 50-55°C. (c) Add sodium chloride to the compounding vessel. Wait until the solid has completely dissolved before proceeding to the next step. (d) Add glycerin to the compounding vessel. Allow sufficient time for complete mixing. (e) Add the remaining Propylene Glycol that is not in the Lipid Blend/Propylene Glycol solution. Allow time for thorough mixing. (f) Reduce mixing rate to reduce turbulence in the compounding vessel. (g) Add the Lipid Blend/Propylene Glycol solution to the compounding vessel. (h) Readjust mixing to original rate. (i) Add additional WFI if necessary. (j) Continue to mix for approximately 25 minutes and assure complete mixing. (k) Verify and adjust the solution to target pH.

20

Step(3):

Step three involves heating the lipid suspension obtained from step (2) to a temperature about equal to or above the highest gel to liquid crystalline phase transition temperature of the lipids present in the solution.

One of the objects of this step is to provide a filterable suspension. A solution/suspension is considered filterable if there is no significant reduction in flow rate within a normal process, and there is no significant increase in the pressure drop in the filtration system.

Experimental data indicates that the lipids in the formulation should be beyond their gel to liquid crystalline phase transition in order to simplify sterile filtration. When the lipids are below the phase transition temperature, the suspension particles are rigid. However, when they are above their respective gel-liquid crystal phase transition temperatures, they are in a more loosely organized configuration and thus, more easily filtered.

DPPC and DPPA show phase transitions of 41°C and 67°C respectively. MPEG5000-DPPE is soluble in water, therefore it does not exhibit a gel-liquid crystal phase transition which is characteristic of most hydrated lipid suspensions.

5 Because the lipids in the preferred formulation all exhibit different gel to liquid phase transitions, the highest phase transition temperature, 67°C, is preferably used to filter the solution. By maintaining temperature at or beyond 67°C, all the lipids are beyond their respective phase transition,

10 assuring the loose configuration while passing through the filters.

Heating may be achieved by jacketing the compounding vessel with a heat exchanging coil. Hot water/steam from a controlled source, e.g., a hot water bath, or a water heater, would deliver sufficient heat to maintain the compounding solution at a set temperature. Other heat sources known to those of skill in the art could also be used.

20 Step (4):

Step four is performed by filtering the lipid suspension through a sterilizing filter. The purpose behind this step being to provide a substantially bacteria-free suspension. A filtrate is considered substantially bacteria-free when the probability of the filtrate to contain at least one colony forming microorganism is less than  $10^{-6}$ .

25

Filtration is preferably done using sterilizing filter cartridges. Also, a means of forcing the solution through the filters may be required (e.g., pumping or pressurizing). Since the solution being filtered needs to be maintained at a temperature at or above the highest gel to liquid crystalline phase transition temperature of the lipids present in the solution, the filtration should be performed at about this same temperature. In order to accomplish this, the filter (e.g., sterilizing filter cartridges) are preferably enclosed in jacketed filter housings which are continuously heated, e.g., by a hot water stream from a

temperature controlled water bath, to ensure that the suspension is above the lipid phase transition temperatures. The temperature of the sterilizing filter is preferably from 50 to 100°C, more preferably from 60 to 90°C, and even more 5 preferably 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80°C.

One or more sterilizing filters may be used to filter the suspension. The required number will be based on their effectiveness at removing bacteria. It is preferred that 10 two filters are used. The size of the filter pores will be limited by the need to provide a bacteria-free suspension. Preferably, 0.2µm hydrophilic filters are used.

A bulk solution of the preferred formulation was continuously filtered through two 0.2µm hydrophilic filters for up to 3 hours at a rate of approximately 1 liter per 15 minute (1 L/min.), i.e., passing a total of 180 liters of the suspension solution through the filters. The experimental results shows that there is no apparent blockage of filters. Lipid assays indicates that there is no measurable loss during the filtration process (due to 20 accumulation in the filter medium).

A bulk solution of the preferred formulation was compounded at 40°C-80°C, and the suspension was cooled to ambient temperature prior to sterile filtration. No apparent clogging of the filters were observed indicating 25 the suspension particle size distribution is well below 0.2µm of the filter pore size. It is desirable to use heat during filtration in order to ensure maximum recover of the lipid blend in the sterile filtrate (i.e., to minimize potential retention of lipid particles in the filter 30 medium).

A preferred procedure for filtering the lipid suspension is as follows: (a) Assure all jacketed filters are at 70°C - 80°C. (b) Assure all valves in the filtration unit are closed. (c) Connect filtration inlet hose to the 35 outlet of the compounding vessel. (d) Open valves to allow solution to pass through the filters. (e) Flush three liters of solution through the filters before collecting filtrate. (f) Continue filtration until complete.

Step (5):

Dispensing the filtered solution into a vial completes step five. Preferably, this step is performed in a controlled aseptic area. One of ordinary skill in the art would recognize that the vial selected and amount of suspension delivered to the vial would depend on the end use considered for the lipid suspension. Dispensing can be achieved via a variety of methods, including pipette, hand-held syringe dispenser (e.g., Filamatic® syringe dispensing machine), or industrial auto dispensing machine (e.g., Cozzoli or TL auto filling machine).

Step (6):

Step six is performed by exchanging the headspace gas of the vials from step five with a perfluorocarbon gas. A preferred method of exchange is to load the dispensed vials into a lyophilizer chamber and replace the vial headspace gas with a perfluorocarbon gas. A preferred gas is perfluoropropane (PFP). Other methods of headspace gas exchange known to those of skill in the art may be employed.

The vials are sealed at the completion of the vial headspace gas exchange cycle. When the lyophilizer chamber pressure is brought back to atmospheric pressure by charging into the chamber with PFP. Vial stoppers are seated to seal the vials.

Step (7):

Step seven involves terminally sterilizing a vial after step six. One method of terminal sterilization is through the use of an autoclave. Also, the sealed vials can be terminally sterilized in a steam sterilizer to further enhance the sterility assurance of the product. Care must be taken in the sterilization process as some degradation of lipids may be observed as a result of autoclaving. Preferably, the vial is sterilized at about 126-130°C for 1 to 10 minutes.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

5


### EXAMPLES

Table 1: Lipid Blend Target Composition

Lipid Name	Common Name	Wt %	Mole %
DPPA	1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt	6.0	10
DPPC	1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine	53.5	82
MPEG5000 DPPE	<i>N</i> -(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt	40.5	8

10

### Lipid Blend Manufacturing Procedure




A flask is charged with toluene (3.3 L), methanol (1.2 L), DPPA (59.6 g), DPPC (535 g), and MPEG5000 DPPE (405 g).

After rinsing solid contact surfaces with 0.9 L methanol, the slurry is warmed to 45-55°C until dissolution is complete.

The solution is filtered and then concentrated in vacuo at 5 35 - 45° C to a thick gel. Methyl *t*-butyl ether (MTBE, 5.4 L) is added and the mixture is slurried at 15-30°C. White solids are collected by centrifugation or vacuum filtration, and washed with MTBE (0.9 L). The solids are then placed in a vacuum oven and dried to constant weight at 40-50°C. The 10 dried Lipid Blend is transferred to a bottle and stored at -15 to -25 °C.

In another embodiment of the lipid blend manufacturing procedure of the present invention, the following procedure 15 may also be used.

#### Alternative Lipid Blend Manufacturing Procedure



20

Phospholipid quantities were adjusted for purity based on a "Use As" value from the certificates of analysis. The

batch size (combined phospholipid weight) of this experiment was 2 kg.

A rotary evaporation flask is charged sequentially with toluene (3,300 mL), methanol (1,200 mL), DPPA (122.9 g; 5 corrected for "use as" purity of 97.0 %), DPPC (1,098.5 g total; 500.8 g from a lot with 98.4 % "use as" purity and 597.7 g from a lot with 96.7 % "use as" purity), and MPEG5000 DPPE ( 815.7 g; corrected for "use as" purity of 99.3 %). After rinsing residual solids into the flask with 10 methanol (900 mL), the flask is placed on a rotary evaporator (no vacuum) and the slurry is warmed to between 45 and 55 °C (external). After dissolution is complete, the external temperature is reduced to between 35 and 45 °C, a vacuum is applied, and the solution is concentrated to a 15 white semi-solid. The flask is removed from the evaporator and solids are broken up with a spatula. The flask is reapplied to the evaporator and concentration is continued. After reaching the endpoint (final vacuum pressure  $\geq$  20 mbar; white, granular, chunky solid), MTBE (5,400 mL) is 20 added through the rotary evaporator's addition tube, the vacuum is discontinued, and the mixture is slurried for 15 to 45 min at 15 to 30 °C. Solids are isolated by either centrifugal or vacuum filtration, rinsed with MTBE (3,800 mL), and dried to constant weight in a vacuum oven (40 to 50 25 °C). Prior to transferring to polyethylene bottles with polypropylene caps, solids are delumped through a screen (0.079 inch mesh), affording 1,966.7 g (98 %) of lipid blend (SG896) as a white solid.

30 The preferred lipid suspension contains:  
1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono  
sodium salt (DPPA);  
1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine  
(DPPC);  
35 N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-  
dipalmitoyl-sn-glycero-3-

Table 2: Preferred Contrast Agent Formulations

Component	A*	B*
NaCl, USP	6.8 mg/mL	6.8 mg/mL
Glycerin, USP	0.1 mL/mL	0.1 mL/mL
Propylene Glycol, USP	0.1 mL/mL	0.1 mL/mL
Lipid Blend**	1 mg/mL	0.75 mg/mL
Perfluoropropane	> 65%	> 65%
pH	6.0 - 7.0	6.0 - 7.0

10 \*Formulation A has 1 mg/mL lipid blend. Formulation B has a lipid blend concentration of 0.75 mg/mL.  
\*\*The lipid blend is consist of 53.5 wt.% of DPPC, 6.0 wt.% of DPPA and 40.5 wt.% of MPEG5000-DPPE.

15 Table 3: Preferred Container and Closure

Component	Type
Vial	Wheaton 2802, B33BA, 2cc, 13mm, Type I, flint tubing vial
Stopper	West V50 4416/50, 13mm, gray butyl lyo, siliconized stoppers
Seal	West 3766, white 13mm, flip-off aluminum seals

The finished product fill volume can be from 1.0-2.0 mL/vial.

20 In the preparation of the preferred formulation, when the lipid blend is directly hydrated with the aqueous matrix solution containing water for injection, sodium chloride,

glycerin and propylene glycol, the filtrates have less lipids as compared to the pre-filtration bulk solution. The loss of lipids varies from 12% to 48%. These results demonstrate that the sterile filtration process is not 5 effectively controlled, and therefore, the final product lipid content is highly variable.

In contrast, using the presently described process, assay results of the lipids in show full recovery of lipids during the filtration process. Variability of assay results 10 around the theoretical targets is within normal assay method variability. Particle size distribution by number, by volume and by reflective intensity of a suspension prepared by first solubilizing lipid blend in propylene glycol indicate that the majority of the particles are less than 50 15 nm in the pre-filtered bulk solution at 55°C as well at 70°C. The particle distribution profile does not change after filtration.

#### UTILITY SECTION

20 The presently claimed process is useful for preparing ultrasound contrast agents. Such agents should be useful for a variety of imaging applications, including enhancing contrast in echocardiographic and radiologic ultrasound images.

25 Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

WHAT IS CLAIMED AS NEW AND DESIRED TO BE SECURED BY LETTER  
PATENT OF UNITED STATES IS:

1. A process for preparing a phospholipid suspension, comprising:
  - 5 (1) contacting a lipid blend with a non-aqueous solvent, whereby the lipid blend substantially dissolves in the non-aqueous solvent; and,
    - (2) contacting the solution from step (1) with an aqueous solution to form a lipid suspension.
- 10 2. A process according to Claim 1, wherein the non-aqueous solvent is selected from propylene glycol, ethylene glycol, and polyethylene glycol 300.
- 15 3. A process according to Claim 2, wherein the non-aqueous solvent is propylene glycol.
4. A process according to Claim 2, wherein the lipid blend, comprises:
  - 20 (a) 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine;
  - (b) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt; and,
  - (c) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt.
- 25 5. A process according to Claim 2, wherein the non-aqueous solvent is heated to a temperature of about 30 to 70°C prior to contacting with the lipid blend.
- 30 6. A process according to Claim 5, wherein the non-aqueous solvent is heated to a temperature of about 50 to 55°C prior to contacting with the lipid blend.
- 35 7. A process according to Claim 2, wherein the ratio of lipid blend to non-aqueous solvent is from about 5 mg of lipid blend per mL of non-aqueous solvent to about 15 mg/mL.

8. A process according to Claim 7, wherein the ratio of lipid blend to non-aqueous solvent is about 10 mg/mL.

9. A process according to Claim 2, wherein in step 5 (2), the aqueous solution is selected from water, saline, a saline/glycerin mixture, and a saline/glycerin/non-aqueous solvent mixture.

10. A process according to Claim 9, wherein the 10 aqueous solution is a saline and glycerin mixture.

11. A process according to Claim 9, wherein the aqueous solution is a saline, glycerin, and propylene glycol mixture.

15 12. A process according to Claim 11, wherein 6.8 mg/mL of sodium chloride are present, 0.1 mL/mL of glycerin are present, 0.1 mL/mL of propylene glycol are present, and about 0.75 to 1.0 mg/mL of the lipid blend are present.

20 13. A process according to Claim 12, wherein 0.75 mg/mL of lipid blend are present.

25 14. A process according to Claim 12, wherein 1.0 mg/mL of lipid blend are present.

15. A process according to Claim 2, wherein in step (2), the aqueous solution is heated to a temperature of about 45 to 60°C prior to contacting with the solution from 30 step (1).

16. A process according to Claim 15, wherein the aqueous solution is heated to a temperature of about 50 to 55°C prior to contacting with the solution from step (1).

35 17. A process according to Claim 1, wherein the process further comprises:

(3) heating the lipid suspension from step (2) to a temperature about equal to or above the highest gel to liquid crystalline phase transition temperature of the lipids present in the suspension.

5

18. A process according to Claim 17, wherein in step (3), the lipid suspension is heated to a temperature of at least about 67°C.

10 19. A process according to Claim 17, wherein the process further comprises:

(4) filtering the lipid suspension through a sterilizing filter.

15 20. A process according to Claim 19, wherein in step (4), the filtration is performed using two sterilizing filter cartridges.

20 21. A process according to Claim 20, wherein in step (4), the sterilizing filter cartridges are at a temperature of from about 70 to 80°C.

25 22. A process according to Claim 21, wherein in step (4), 0.2µm hydrophilic filters are used.

25

23. A process according to Claim 19, wherein the process further comprises:

(5) dispensing the filtered solution from step (4) into a vial.

30

24. A process according to Claim 23, wherein the process further comprises:

(6) exchanging the headspace gas of the vial from step (5) with a perfluorocarbon gas.

35

25. A process according to Claim 24, wherein the perfluorocarbon gas is perfluoropropane.

26. A process according to Claim 25, wherein exchange of headspace gas is performed using a lyophilizing chamber.

27. A process according to Claim 24, wherein the  
5 process further comprises:

(7) sterilizing the vial from step (6).

28. A process according to Claim 27, wherein in step  
(7), the vial is sterilized at about 126-130°C for 1 to 10  
10 minutes.

29. A process for preparing a lipid blend, comprising:

(a) contacting at least two lipids with a first non-aqueous solvent;

15 (b) concentrating the solution to a thick gel;

(c) contacting the thick gel with a second non-aqueous solvent; and,

(d) collecting the resulting solids.

20 30. A process according to Claim 29, wherein in step (a), the lipids are:

(i) 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine;

(ii) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt; and,

25 (iii) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt.

31. A process according to Claim 30, wherein in step 30 (a), the first non-aqueous solvent is a mixture of methanol and toluene.

32. A process according to Claim 30, wherein in step 35 (c), the second non-aqueous solvent is a methyl t-butyl ether.

33. A process according to Claim 30, wherein in step (a), the solution is warmed to a temperature sufficient to complete dissolution of the lipids into the solvent.

5 34. A process according to Claim 33, wherein in step (a), the solution is warmed to about 25 to 75°C.

10 35. A process according to Claim 30, wherein in step (d), the solids collected are washed with methyl *t*-butyl ether and dried in vacuo.

36. A phospholipid suspension, comprising:  
(a) a lipid blend in an amount of about 0.75 - 1.0 mg/mL of suspension;  
15 (b) sodium chloride in an amount of about 6.8 mg/mL of suspension;  
(c) glycerin in an amount of about 0.1 mL/mL of suspension;  
(d) propylene glycol in an amount of about 0.1 mL/mL of suspension; and  
20 (e) water;  
wherein the suspension is prepared by the process, comprising:  
(1) contacting a lipid blend with a non-aqueous solvent, whereby the lipid blend substantially dissolves in the non-aqueous solvent;  
25 (2) contacting the solution from step (1) with an aqueous solution to form a lipid suspension;  
(3) heating the lipid suspension from step (2) to a temperature about equal to or above the highest gel to liquid crystalline phase transition temperature of the lipids present in the suspension; and,  
30 (4) filtering the lipid suspension through a sterilizing filter.

35 37. A phospholipid suspension according to Claim 36, wherein the lipid blend, comprises:  
(a) 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine;

(b) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt; and,

(c) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt.

38. A phospholipid suspension according to Claim 37, wherein the non-aqueous solvent is heated to a temperature of about 50 to 55°C prior to contacting with the lipid blend.

39. A phospholipid suspension according to Claim 37, wherein the ratio of lipid blend to non-aqueous solvent is about 10 mg/mL.

40. A phospholipid suspension according to Claim 37, wherein the aqueous solution is a saline, glycerin, and propylene glycol mixture.

41. A phospholipid suspension according to Claim 40, wherein 0.75 mg/mL of lipid blend are present.

42. A phospholipid suspension according to Claim 37, wherein the aqueous solution is heated to a temperature of about 50 to 55°C prior to contacting with the solution from step (1).

43. A phospholipid suspension according to Claim 37, wherein in step (3), the lipid suspension is heated to a temperature of at least about 67°C.

44. A phospholipid suspension according to Claim 43, wherein in step (4), two 0.2µm hydrophilic filters are used.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>A61K 9/127, 49/00</b></p>		<p><b>A3</b></p>	<p>(11) International Publication Number: <b>WO 99/36104</b> (43) International Publication Date: <b>22 July 1999 (22.07.99)</b></p>
<p>(21) International Application Number: <b>PCT/US99/00747</b></p>		<p>(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p>	
<p>(22) International Filing Date: <b>14 January 1999 (14.01.99)</b></p>		<p><b>Published</b> <i>With international search report.</i></p>	
<p>(30) Priority Data: <b>60/071,332 14 January 1998 (14.01.98) US</b></p>		<p>(88) Date of publication of the international search report: <b>13 January 2000 (13.01.00)</b></p>	
<p>(71) Applicant: <b>DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US).</b></p>			
<p>(72) Inventors: <b>HUI, Poh, K.; 45 Wareland Road, Wellesley, MA 02181 (US). BISHOP, John, E.; 878 Townsend Road, Groton, MA 01450 (US). MADRIGAL, Eleodoro, S., Jr.; Apartment 12, 14B Strawberry Hill Road, Acton, MA 01720 (US).</b></p>			
<p>(74) Agent: <b>O'BRIEN, Maureen, P.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).</b></p>			
<p>(54) Title: <b>PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND, AND CONTRAST AGENTS BASED ON THESE</b></p>			
<p>(57) Abstract</p> <p>The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/00747

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K9/127 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 349 429 A (CENTRE NAT RECH SCIENT) 3 January 1990 (1990-01-03) examples claim 1 ---	1-28, 36-44
Y	US 5 637 289 A (KLAIVENESS JO ET AL) 10 June 1997 (1997-06-10) example 5 ---	1-28, 36-44
Y	WO 95 32006 A (IMARX PHARMACEUTICAL CORP) 30 November 1995 (1995-11-30) examples 1-3 ---	1-28 36-44
P, Y	WO 98 47487 A (DUMEX LTD AS ; NIELSEN LISE SYLVEST (DK)) 29 October 1998 (1998-10-29) page 66 - page 67 ---	1-28
P, X	---	1, 17-23 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

12 August 1999

Date of mailing of the international search report

01.09.99

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Dullaart, A

**INTERNATIONAL SEARCH REPORT**

Inte. onal Application No  
PCT/US 99/00747

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 31196 A (IMARX PHARMACEUTICAL CORP) 10 October 1996 (1996-10-10)	1-35
X	example 1 ---	36-44
Y	G. GREGODIADIS (EDITOR): "Liposome Technology, Volume 1: Preparation of liposomes" 1984, CRC PRESS, INC., BOCA RATON, US XP002101586 13391 page 29 - page 35 & D.W. DEAMER: "PREPARATION OF SOLVENT VAPORIZATION LIPOSOMES" ---	1-23
Y	OHKI K ET AL: "SHORT AND LONG RANGE CALCIUM-INDUCED LATERAL PHASE SEPARATIONS IN TERNARY MIXTURES OF PHOSPHATIDIC ACID PHOSPHATIDYLCHOLINE AND PHOSPHATIDYLETHANOLAMINE" CHEMISTRY AND PHYSICS OF LIPIDS, 1989, VOL. 50, NO. 2, PAGE(S) 109-118., XP002101581	1-44
X	abstract page 110, left-hand column page 113; figure 4 page 117 ---	36-44
A	MARUYAMA KAZUO ET AL.: "Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)." BIOCHIMICA ET BIOPHYSICA ACTA, 1992, VOL. 1128, PAGES 44-49, XP002101582 table 1 figures 1-3 ---	1-28, 36-44
A	BEDU-ADDO FK ET AL: "Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery." PHARM RES, MAY 1996, VOL. 13, NO. 5, PAGE(S) 710-717, XP002101583 paragraph 'RESULTS' ---	1-28, 36-44
	-/-	

**INTERNATIONAL SEARCH REPORT**

International Application No  
PCT/US 99/00747

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	BELSITO S. ET AL: "Sterically stabilized liposomes of DPPC/DPPE-PEG:2000. A spin label ESR and spectrophotometric study" BIOPHYSICAL CHEMISTRY, 5-10-1998, VOL. 75, NO. 1, PAGE(S) 33-43, XP002101584 figure 1 figures 5,6; table 2 ---	1-28, 36-44
Y, P		29-35
A	NIKOLOVA AN ET AL: "Effect of grafted PEG-2000 on the size and permeability of vesicles." BIOCHIM BIOPHYS ACTA, 22-11-1996, VOL. 1304, NO. 2, PAGE(S) 120-128, XP002101585 the whole document ---	1-23, 36-44
Y	WO 96 08234 A (IMARX PHARMACEUTICAL CORP) 21 March 1996 (1996-03-21)	1-28
X	examples ---	36-44
P, Y	WO 98 10799 A (IMARX PHARMACEUTICAL CORP) 19 March 1998 (1998-03-19)	1-28
P, X	example 1 ---	36-44
Y	WO 96 40285 A (IMARX PHARMACEUTICAL CORP); UNGER EVAN C (US); SHEN DEKANG (US); WU 19 December 1996 (1996-12-19)	1-28
X	example 6 ---	36-44
P, Y	WO 98 51284 A (IMARX PHARMACEUTICAL CORP) 19 November 1998 (1998-11-19)	1-28
P, X	example 12 ---	36-44
Y	WO 97 40858 A (IMARX PHARMACEUTICAL CORP) 6 November 1997 (1997-11-06)	1-28
X	examples ---	36-44
Y	WO 95 15118 A (MATSUNAGA TERRY; UNGER EVAN C (US); YELLOWHAIR DAVID (US)) 8 June 1995 (1995-06-08)	1-28
X	page 25 examples claims 19,20 ---	29-44
E	EP 0 901 793 A (IMARX PHARMACEUTICAL CORP) 17 March 1999 (1999-03-17) examples 1,2 -----	1-28, 36-44

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US 99/00747**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: **1-44 in part** because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

**1. Claims: 1-23 in part, and 36-44**

The process for preparing a phospholipid suspension as described in claims 1-23, and the phospholipid suspension thus obtained.

**2. Claims: 1-23 in part, and 24-28**

The process for preparing a perfluorocarbon-containing contrast agent according to these claims.

**3. Claims: 29-35**

The process for the prepreparation of a lipid blend according to these claims.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

**Continuation of Box I.2**

**Claims Nos.: 1-44 in part**

In view of the large number of compositions, which are defined by the general definition in the claims, the search had to be restricted for economic reasons. The search was limited to the compositions for which pharmacological data was given and/or the compositions mentioned in the claims, and to the general idea underlying the application (see guidelines, Chapter III, paragraph 2.3).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No	
PCT/US 99/00747	

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0349429	A	03-01-1990	FR 2634375 A		26-01-1990
			AT 85888 T		15-03-1993
			DE 68904999 T		12-06-1997
			ES 2054053 T		01-08-1994
			GR 3007265 T		30-07-1993
			GR 3022121 T		31-03-1997
			JP 2118858 C		06-12-1996
			JP 2149336 A		07-06-1990
			JP 8024840 B		13-03-1996
			KR 9614869 B		21-10-1996
			US 5174930 A		29-12-1992
US 5637289	A	10-06-1997	AU 676148 B		06-03-1997
			AU 3348593 A		03-08-1993
			EP 0620745 A		26-10-1994
			FI 943264 A		04-08-1994
			JP 7505137 T		08-06-1995
			NO 942562 A		07-07-1994
			AT 168564 T		15-08-1998
			AU 676146 B		06-03-1997
			AU 3348393 A		03-08-1993
			CA 2127704 A		22-07-1993
			DE 69319888 D		27-08-1998
			DE 69319888 T		11-02-1999
			WO 9313802 A		22-07-1993
			EP 0620743 A		26-10-1994
			ES 2120493 T		01-11-1998
			JP 7505135 T		08-06-1995
			NO 942560 A		07-07-1994
			US 5567412 A		22-10-1996
			US 5614169 A		25-03-1997
WO 9532006	A	30-11-1995	US 5874062 A		23-02-1999
			AU 700799 B		14-01-1999
			AU 2601395 A		18-12-1995
			AU 2645495 A		18-12-1995
			CA 2191079 A		30-11-1995
			CN 1160357 A		24-09-1997
			CN 1149259 A		07-05-1997
			EP 0760684 A		12-03-1997
			EP 0762899 A		19-03-1997
			JP 10500691 T		20-01-1998
			JP 10500692 T		20-01-1998
			WO 9532005 A		30-11-1995
			US 5736121 A		07-04-1999
WO 9847487	A	29-10-1998	AU 6919598 A		13-11-1998
WO 9631196	A	10-10-1996	US 5705187 A		06-01-1998
			AU 5375596 A		23-10-1996
			BR 9604786 A		07-07-1998
			CA 2217494 A		10-10-1996
			EP 0818989 A		21-01-1998
WO 9608234	A	21-03-1996	US 5773024 A		30-06-1998
			AU 2185095 A		19-06-1995
			AU 3146595 A		29-03-1996
			BR 9509011 A		30-09-1997

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No	
PCT/US 99/00747	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9608234 A		CA 2177713 A		08-06-1995
		CA 2200061 A		21-03-1996
		CN 1158082 A		27-08-1997
		EP 0740528 A		06-11-1996
		EP 0788348 A		13-08-1997
		JP 10505900 T		09-06-1998
		JP 9506098 T		17-06-1997
		WO 9515118 A		08-06-1995
		US 5733572 A		31-03-1998
		US 5922304 A		13-07-1999
		US 5705187 A		06-01-1998
		US 5656211 A		12-08-1997
WO 9810799 A	19-03-1998	AU 4089897 A		02-04-1998
		AU 4235697 A		02-04-1998
		WO 9810798 A		19-03-1998
		US 5846517 A		08-12-1998
WO 9640285 A	19-12-1996	AU 6270396 A		30-12-1996
		CA 2218541 A		19-12-1996
		EP 0831932 A		01-04-1998
WO 9851284 A	19-11-1998	AU 7378798 A		08-12-1998
		AU 7796198 A		08-12-1998
		WO 9851282 A		19-11-1998
WO 9740858 A	06-11-1997	US 5776429 A		07-07-1998
		AU 2451097 A		19-11-1997
		CN 1216925 A		19-05-1999
		EP 0923383 A		23-06-1999
WO 9515118 A	08-06-1995	US 5585112 A		17-12-1996
		US 5542935 A		06-08-1996
		US 5773024 A		30-06-1998
		US 5733572 A		31-03-1998
		AU 1004399 A		04-03-1999
		AU 2185095 A		19-06-1995
		AU 696056 B		27-08-1998
		AU 6953794 A		03-01-1995
		AU 683900 B		27-11-1997
		AU 7043194 A		03-01-1995
		AU 8840698 A		04-02-1999
		CA 2164846 A		22-12-1994
		CA 2177713 A		08-06-1995
		CN 1137748 A		11-12-1996
		EP 0802788 A		29-10-1997
		EP 0712293 A		22-05-1996
		EP 0740528 A		06-11-1996
		JP 8511523 T		03-12-1996
		JP 8511526 T		03-12-1996
		JP 9506098 T		17-06-1997
		WO 9428874 A		22-12-1994
		WO 9428780 A		22-12-1998
		US 5922304 A		13-07-1999
		US 5705187 A		06-01-1998
		US 5853752 A		29-12-1998
		US 5656211 A		12-08-1997
		US 5776429 A		07-07-1998

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No	
PCT/US 99/00747	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515118 A		CN 1125389 A CN 1125393 A AU 3146595 A BR 9509011 A CA 2200061 A CN 1158082 A EP 0788348 A JP 10505900 T WO 9608234 A	26-06-1996 26-06-1996 29-03-1996 30-09-1997 21-03-1996 27-08-1997 13-08-1997 09-06-1998 21-03-1996
EP 0901793 A	17-03-1999	NONE	